ES3058680T3 - Cyclohexyl acid isoxazole azines as lpa antagonists - Google Patents
Cyclohexyl acid isoxazole azines as lpa antagonistsInfo
- Publication number
- ES3058680T3 ES3058680T3 ES18830677T ES18830677T ES3058680T3 ES 3058680 T3 ES3058680 T3 ES 3058680T3 ES 18830677 T ES18830677 T ES 18830677T ES 18830677 T ES18830677 T ES 18830677T ES 3058680 T3 ES3058680 T3 ES 3058680T3
- Authority
- ES
- Spain
- Prior art keywords
- methyl
- lpa
- amino
- oxy
- fibrosis
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D261/00—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings
- C07D261/02—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings
- C07D261/06—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings having two or more double bonds between ring members or between ring members and non-ring members
- C07D261/08—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings having two or more double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201762607398P | 2017-12-19 | 2017-12-19 | |
| PCT/US2018/066111 WO2019126086A1 (en) | 2017-12-19 | 2018-12-18 | Cyclohexyl acid isoxazole azines as lpa antagonists |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ES3058680T3 true ES3058680T3 (en) | 2026-03-12 |
Family
ID=65003576
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ES18830677T Active ES3058680T3 (en) | 2017-12-19 | 2018-12-18 | Cyclohexyl acid isoxazole azines as lpa antagonists |
Country Status (7)
| Country | Link |
|---|---|
| US (1) | US11319309B2 (https=) |
| EP (1) | EP3728209B1 (https=) |
| JP (1) | JP7526096B2 (https=) |
| KR (1) | KR102828422B1 (https=) |
| CN (1) | CN111479807B (https=) |
| ES (1) | ES3058680T3 (https=) |
| WO (1) | WO2019126086A1 (https=) |
Families Citing this family (24)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AR108838A1 (es) | 2016-06-21 | 2018-10-03 | Bristol Myers Squibb Co | Ácidos de carbamoiloximetil triazol ciclohexilo como antagonistas de lpa |
| WO2019126089A1 (en) * | 2017-12-19 | 2019-06-27 | Bristol-Myers Squibb Company | Cyclohexyl acid pyrazole azines as lpa antagonists |
| EP4011875A1 (en) | 2017-12-19 | 2022-06-15 | Bristol-Myers Squibb Company | Triazole n-linked carbamoyl cyclohexyl acids as lpa antagonists |
| KR102788997B1 (ko) | 2018-09-18 | 2025-03-28 | 브리스톨-마이어스 스큅 컴퍼니 | Lpa 길항제로서의 옥사비시클로 산 |
| ES2946657T3 (es) | 2018-09-18 | 2023-07-24 | Bristol Myers Squibb Co | Acidos ciclopentílicos como antagonistas de LPA |
| CN111434655A (zh) * | 2019-01-15 | 2020-07-21 | 武汉朗来科技发展有限公司 | 溶血磷脂酸受体拮抗剂及其制备方法 |
| AU2020384883B2 (en) | 2019-11-15 | 2023-11-16 | Gilead Sciences, Inc. | Triazole carbamate pyridyl sulfonamides as LPA receptor antagonists and uses thereof |
| CN114746425A (zh) | 2019-12-12 | 2022-07-12 | 奇斯药制品公司 | 作为lpa受体2抑制剂的噻吩并嘧啶衍生物 |
| WO2021116259A1 (en) | 2019-12-12 | 2021-06-17 | Chiesi Farmaceutici S.P.A. | Aromatic amido derivatives as lpa receptor 2 inhibitors |
| JP2023505704A (ja) | 2019-12-12 | 2023-02-10 | キエシ・フアルマチエウテイチ・ソチエタ・ペル・アチオニ | Ｌｐａ受容体２阻害剤としてのキナゾリン誘導体 |
| CN115867556B (zh) | 2020-06-03 | 2025-05-06 | 吉利德科学公司 | Lpa受体拮抗剂及其用途 |
| TWI843503B (zh) | 2020-06-03 | 2024-05-21 | 美商基利科學股份有限公司 | Lpa受體拮抗劑及其用途 |
| WO2022013378A1 (en) | 2020-07-16 | 2022-01-20 | Chiesi Farmaceutici S.P.A. | Amido cyclohexane acid derivatives as lpa receptor inhibitors |
| WO2022174883A1 (en) | 2021-02-16 | 2022-08-25 | Chiesi Farmaceutici S.P.A. | 5-membered heterocyclyl derivatives as dual lpa receptor 1 and lpa receptor 2 inhibitors |
| WO2022174882A1 (en) | 2021-02-16 | 2022-08-25 | Chiesi Farmaceutici S.P.A. | 5-membered heterocyclyl carbamate derivatives as dual lpa receptor 1 and lpa receptor 2 inhibitors |
| JP2024512557A (ja) | 2021-03-24 | 2024-03-19 | キエシ・フアルマチエウテイチ・ソチエタ・ペル・アチオニ | Ｌｐａ受容体２阻害物質としての８－シクロ－置換キナゾリン誘導体 |
| TWI853704B (zh) | 2021-05-11 | 2024-08-21 | 美商基利科學股份有限公司 | Lpa受體拮抗劑及其用途 |
| KR20240007233A (ko) | 2021-05-13 | 2024-01-16 | 길리애드 사이언시즈, 인코포레이티드 | Lpa 수용체 길항제 및 이의 용도 |
| WO2023107938A1 (en) | 2021-12-08 | 2023-06-15 | Gilead Sciences, Inc. | Lpa receptor antagonists and uses thereof |
| WO2023118253A1 (en) | 2021-12-23 | 2023-06-29 | Chiesi Farmaceutici S.P.A. | Cyclohexane acid derivatives as lpa receptor inhibitors |
| AR128613A1 (es) | 2022-02-25 | 2024-05-29 | Lhotse Bio Inc | Compuestos y composiciones para el tratamiento de afecciones asociadas con la actividad del receptor de lpa |
| EP4490150A1 (en) | 2022-03-08 | 2025-01-15 | Chiesi Farmaceutici S.p.A. | Amido cyclopropyl derivatives as lpa receptor inhibitors |
| AU2023238460A1 (en) * | 2022-03-25 | 2024-10-31 | Vasthera Co., Ltd. | 3-phenylisoxazole derivative, and pharmaceutical composition for preventing or treating eye disease, containing same as active ingredient |
| WO2026005060A1 (ja) * | 2024-06-28 | 2026-01-02 | 三菱ケミカル株式会社 | 化合物、その化合物の製造方法、その化合物を含む感光性組成物、その組成物を用いたパターン形成方法、基板及び基板の製造方法 |
Family Cites Families (19)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ATE420878T1 (de) | 2000-02-18 | 2009-01-15 | Kyowa Hakko Kirin Co Ltd | Isoxazol- und thiazolverbindungen und ihre verwendung als medikamente |
| WO2002062389A1 (en) | 2001-02-08 | 2002-08-15 | Ono Pharmaceutical Co., Ltd. | Remedies for urinary diseases comprising lpa receptor controlling agents |
| JP4692281B2 (ja) | 2003-08-05 | 2011-06-01 | 味の素株式会社 | 新規アゾール化合物 |
| WO2011017350A2 (en) * | 2009-08-04 | 2011-02-10 | Amira Pharmaceuticals, Inc. | Compounds as lysophosphatidic acid receptor antagonists |
| US8221753B2 (en) * | 2009-09-30 | 2012-07-17 | Tracon Pharmaceuticals, Inc. | Endoglin antibodies |
| GB2474748B (en) | 2009-10-01 | 2011-10-12 | Amira Pharmaceuticals Inc | Polycyclic compounds as lysophosphatidic acid receptor antagonists |
| GB2474120B (en) * | 2009-10-01 | 2011-12-21 | Amira Pharmaceuticals Inc | Compounds as Lysophosphatidic acid receptor antagonists |
| EA201390821A1 (ru) | 2010-12-07 | 2013-10-30 | Амира Фармасьютикалс, Инк. | Антагонисты рецепторов лизофосфатидной кислоты и их применение |
| US8785442B2 (en) | 2011-01-30 | 2014-07-22 | Curegenix, Inc. | Compound as antagonist of lysophosphatidic acid receptor, composition, and use thereof |
| EP2694472B1 (en) | 2011-04-05 | 2020-03-11 | Takeda Pharmaceutical Company Limited | Sulfonamide derivative and use thereof |
| WO2012138648A1 (en) | 2011-04-06 | 2012-10-11 | Irm Llc | Compositions and methods for modulating lpa receptors |
| WO2013070879A1 (en) * | 2011-11-10 | 2013-05-16 | Bristol-Myers Squibb Company | Methods for treating spinal cord injury with lpa receptor antagonists |
| US20140329871A1 (en) | 2011-12-04 | 2014-11-06 | Angion Biomedica Corp. | Small molecule anti-fibrotic compounds and uses thereof |
| SG11201407228PA (en) * | 2012-06-20 | 2014-12-30 | Hoffmann La Roche | N-aryltriazole compounds as lpar antagonists |
| UA109868C2 (ru) * | 2012-06-20 | 2015-10-12 | Ф. Хоффманн-Ля Рош Аг | Соединения n-алкилтриазола как антагонисты лизофосфатидной кислоты (lpar) |
| DK2988743T3 (da) | 2013-03-15 | 2021-03-01 | Epigen Biosciences Inc | Heterocykliske forbindelser, der kan anvendes til behandling af sygdom |
| JP2017095366A (ja) | 2015-11-18 | 2017-06-01 | 持田製薬株式会社 | 新規ビアリールアミド誘導体 |
| AR108838A1 (es) | 2016-06-21 | 2018-10-03 | Bristol Myers Squibb Co | Ácidos de carbamoiloximetil triazol ciclohexilo como antagonistas de lpa |
| EP4011875A1 (en) | 2017-12-19 | 2022-06-15 | Bristol-Myers Squibb Company | Triazole n-linked carbamoyl cyclohexyl acids as lpa antagonists |
-
2018
- 2018-12-18 EP EP18830677.3A patent/EP3728209B1/en active Active
- 2018-12-18 ES ES18830677T patent/ES3058680T3/es active Active
- 2018-12-18 KR KR1020207020554A patent/KR102828422B1/ko active Active
- 2018-12-18 WO PCT/US2018/066111 patent/WO2019126086A1/en not_active Ceased
- 2018-12-18 US US16/954,552 patent/US11319309B2/en active Active
- 2018-12-18 JP JP2020533847A patent/JP7526096B2/ja active Active
- 2018-12-18 CN CN201880080917.3A patent/CN111479807B/zh active Active
Also Published As
| Publication number | Publication date |
|---|---|
| CN111479807A (zh) | 2020-07-31 |
| EP3728209A1 (en) | 2020-10-28 |
| KR102828422B1 (ko) | 2025-07-01 |
| US20200317656A1 (en) | 2020-10-08 |
| CN111479807B (zh) | 2024-11-26 |
| EP3728209B1 (en) | 2025-12-24 |
| WO2019126086A1 (en) | 2019-06-27 |
| JP7526096B2 (ja) | 2024-07-31 |
| EP3728209C0 (en) | 2025-12-24 |
| JP2021506878A (ja) | 2021-02-22 |
| US11319309B2 (en) | 2022-05-03 |
| KR20200100722A (ko) | 2020-08-26 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ES3058680T3 (en) | Cyclohexyl acid isoxazole azines as lpa antagonists | |
| ES2898364T3 (es) | Acidos carbamoilciclohexílicos ligados a N triazol como antagonistas de LPA | |
| ES2936517T3 (es) | Triazol azinas de ácido ciclohexílico como antagonistas de LPA | |
| ES2962367T3 (es) | Acidos carbamoil ciclohexílicos N-enlazados a pirazol como antagonistas de receptores del ácido lisofosfatídico (LPA) | |
| ES2938863T3 (es) | Triazol azoles de ácido ciclohexilo como antagonistas de ácido lisofosfatídico (LPA) | |
| US11261180B2 (en) | Cyclohexyl acid isoxazole azoles as LPA antagonists | |
| ES3054967T3 (en) | Triazole carboxylic acids as lpa antagonists | |
| US11447475B2 (en) | Isoxazole N-linked carbamoyl cyclohexyl acids as LPA antagonists | |
| CN112041302B (zh) | 作为lpa拮抗剂的吡唑o-连接的氨基甲酰基环己基酸 | |
| EP3852746B1 (en) | Cyclopentyl acids as lpa antagonists | |
| US11312706B2 (en) | Cyclohexyl acid pyrazole azines as LPA antagonists | |
| EP3986553B1 (en) | Cyclobutyl carboxylic acids as lpa antagonists | |
| US11352345B2 (en) | Cyclohexyl acid pyrazole azoles as LPA antagonists | |
| ES2948793T3 (es) | Acidos cicloheptílicos como antagonistas de LPA | |
| BR112020011776B1 (pt) | Ácidos de carbamoil ciclo-hexila n-ligados a triazol como antagonistas de lpa, composição e usos |